Integer (NYSE:ITGR) Price Target Raised to $150.00

Integer (NYSE:ITGR - Free Report) had its price target upped by Benchmark from $140.00 to $150.00 in a report issued on Friday,Benzinga reports. Benchmark currently has a buy rating on the medical equipment provider's stock.

Other research analysts also recently issued research reports about the stock. Citigroup upped their price objective on shares of Integer from $130.00 to $145.00 and gave the company a "neutral" rating in a research note on Wednesday, December 11th. KeyCorp upped their price target on shares of Integer from $144.00 to $154.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Piper Sandler reiterated an "overweight" rating and issued a $140.00 price target (up previously from $125.00) on shares of Integer in a report on Friday, October 25th. Truist Financial upped their price objective on Integer from $147.00 to $163.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Finally, Oppenheimer cut Integer from an "outperform" rating to a "market perform" rating in a report on Friday. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Integer has a consensus rating of "Moderate Buy" and a consensus target price of $147.67.

Integer Trading Up 0.9 %

Shares of ITGR traded up $1.09 on Friday, hitting $128.07. 472,349 shares of the stock traded hands, compared to its average volume of 265,979. Integer has a 1 year low of $102.14 and a 1 year high of $146.36. The stock's 50 day moving average is $137.51 and its two-hundred day moving average is $132.81. The firm has a market capitalization of $4.31 billion, a P/E ratio of 38.12, a P/E/G ratio of 1.72 and a beta of 1.13. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62.

Integer (NYSE:ITGR - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts' consensus estimates of $1.46 by ($0.03). The business had revenue of $449.50 million for the quarter, compared to analysts' expectations of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. As a group, sell-side analysts predict that Integer will post 6.01 earnings per share for the current year.

Institutional Investors Weigh In On Integer

Several institutional investors and hedge funds have recently modified their holdings of the stock. Mather Group LLC. raised its holdings in shares of Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 143 shares during the period. Lee Danner & Bass Inc. purchased a new stake in shares of Integer during the fourth quarter valued at approximately $27,000. Huntington National Bank raised its stake in shares of Integer by 8,933.3% during the third quarter. Huntington National Bank now owns 271 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 268 shares during the period. R Squared Ltd purchased a new position in shares of Integer in the fourth quarter valued at $44,000. Finally, Sterling Capital Management LLC grew its holdings in Integer by 472.9% during the 4th quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 279 shares in the last quarter. Hedge funds and other institutional investors own 99.29% of the company's stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.